Icrucumab

BIOLOGICAL2 trials

Sponsors

Eli Lilly and Company

Conditions

Carcinoma of Renal PelvisCarcinoma of UreterCarcinoma of Urinary TractColon CancerRectal CancerUrethral Carcinoma

Phase 2

A Study of Ramucirumab or Icrucumab in Colorectal Cancer

CompletedNCT01111604

Eli Lilly and CompanyColon Cancer, Rectal Cancer

Start: 2010-08-31End: 2013-12-31Updated: 2019-08-06

Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma

CompletedNCT01282463

Eli Lilly and CompanyCarcinoma of Renal Pelvis, Carcinoma of Ureter, Carcinoma of Urinary Tract +1

Start: 2011-04-30End: 2015-03-31Updated: 2019-09-09

Related Papers

Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy.

2016-10-1125 citations

Interim results of a randomized phase 2 study of docetaxel with ramucirumab versus docetaxel in second-line advanced or metastatic urothelial carcinoma.

Journal of Clinical Oncology2015-03-0115 citations